Korean pharmaceutical companies are leveraging decades of research and development and trusted ingredients to capture growing demand for dermacosmetics amid the K-beauty boom.

Investing.com -- Perrigo said on Monday it has agreed to sell its Dermacosmetics business to Kairos Bidco, an investment vehicle backed by KKR, for up to €327 million as part of its strategy to streamline its portfolio. The deal includes €300 million in upfront cash payment and up to €27 million in milestone payments over a three-year period, according to the terms of the agreement. The Dermacosmetics unit includes several brands such as ACO, Biodermal, Emolium and Iwostin. The business generated net sales of approximately €125 million in 2024. Perrigo plans to use the proceeds from the transaction for capital allocation priorities, including strengthening its balance sheet. The transaction is expected to close in the first quarter of 2026. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. With PRGO making headlines, savvy investors are asking: Is it truly valued fairly? In a market full of overpriced darlings, identifying true value can be challenging. InvestingPro's advanced AI algorithms have analyzed PRGO alongside thousands of other stocks to uncover hidden gems. These undervalued stocks, potentially including PRGO, could offer substantial returns as the market corrects. In 2024 alone, our AI identified several undervalued stocks that later surged by 30 or more. Is PRGO poised for similar growth? Don't miss the opportunity to find out.

Perrigo Company plc has finalized the sale of its Dermacosmetics brand to Karo Healthcare, receiving €306 million to reduce debt. This decision aligns with Perrigo's strategic focus.

Korean dermacosmetic brand MEDIHEAL opens its official store on Rakuten Market, introducing exclusive offers and products for enhanced skincare.

Perrigo (NYSE: PRGO) reported first-quarter 2026 continuing-operations results. Core net sales were $842M, down 8.3% year-over-year (Core organic -11.0%). Reported diluted EPS was $(2.81) driven by a $330.8M goodwill impairment. Core adjusted operating margin was 12.8% and All In adjusted EPS was $0.43.The company completed the post-quarter sale of its Dermacosmetics business with €305.6M upfront proceeds (up to €332.6M total) to support debt reduction, and reaffirmed full-year 2026 outlook with expected H2 improvement.

The sold unit generated about €120M in 2025 sales and 5% of adjusted operating income. Perrigo expects the €306M net proceeds to reduce debt.

Perrigo (NYSE: PRGO) has announced an agreement to sell its Dermacosmetics branded business to KKR-managed Kairos Bidco AB for up to €327 million. The deal includes €300 million in upfront cash and up to €27 million in potential milestone payments tied to net sales performance over three years.The transaction, expected to close in Q1 2026, is part of Perrigo's 'Three-S' strategic plan to Stabilize, Streamline, and Strengthen the organization. The divested brands include ACO, Biodermal, Emolium, and Iwostin, which generated approximately €125 million in net sales and about 5% of Perrigo's 2024 adjusted operating income.Proceeds will be directed towards previously announced capital allocation priorities, including strengthening the company's balance sheet. The deal remains subject to regulatory approvals and works council consultation.

A complete analysis of the latest 2025 K-Beauty trends! This ultimate guide covers must-buy skincare and makeup for foreign tourists, insider tips for shopping at Olive Young and duty-free stores, and...

Company Advanced its 'Three-S' Plan (Stabilize, Streamline, and Strengthen) with Recently Announced Agreement to Sell Dermacosmetics Business, Scaling of Global Operating Growth Model, and Upgraded Brand Building Capabilities that are Delivering Results Solid Execution Amid Challenging...

Transaction Advances Company's 'Three-S' Plan to Streamline its Portfolio and Strengthen Focus on its 'High-Grow' Brands Total Consideration of Up to €327 Million, Consisting of €300 Million in Upfront Cash and Up to €27 Million in Potential Future Milestone Payments Expected Net Proceeds...